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OBJECTIVE: Glucose intolerance is frequently associated with an altered plasma lipid profile and increased
cardiovascular disease risk. Nonetheless, lipid metabolism is scarcely studied in normolipidemic glucose-intolerant
patients. The aim of this study was to investigate whether important lipid metabolic parameters, such as the kinetics
of LDL free and esterified cholesterol and the transfer of lipids to HDL, are altered in glucose-intolerant patients
with normal plasma lipids.
METHODS: Fourteen glucose-intolerant patients and 15 control patients were studied; none of the patients had
cardiovascular disease manifestations, and they were paired for age, sex, race and co-morbidities. A nanoemulsion
resembling a LDL lipid composition (LDE) labeled with 14C-cholesteryl ester and 3H-free cholesterol was
intravenously injected, and blood samples were collected over a 24-h period to determine the fractional clearance
rate of the labels by compartmental analysis. The transfer of free and esterified cholesterol, triglycerides and
phospholipids from the LDE to HDL was measured by the incubation of the LDE with plasma and radioactivity
counting of the supernatant after chemical precipitation of non-HDL fractions.
RESULTS: The levels of LDL, non-HDL and HDL cholesterol, triglycerides, apo A1 and apo B were equal in both
groups. The 14C-esterified cholesterol fractional clearance rate was not different between glucose-intolerant and
control patients, but the 3H-free- cholesterol fractional clearance rate was greater in glucose-intolerant patients
than in control patients. The lipid transfer to HDL was equal in both groups.
CONCLUSION: In these glucose-intolerant patients with normal plasma lipids, a faster removal of LDE free
cholesterol was the only lipid metabolic alteration detected in our study. This finding suggests that the dissociation
of free cholesterol from lipoprotein particles occurs in normolipidemic glucose intolerance and may participate in
atherogenic signaling.
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INTRODUCTION
Insulin resistance, which leads to common disorders such
as glucose intolerance (GI), metabolic syndrome and type 2
diabetes, affects glucose homeostasis and the regulation of
plasma lipids (1,2). Dyslipidemia that results from insulin
resistance leads to the development of cardiovascular disease
not only in overt type 2 diabetes patients but also in subjects
with GI (2). Interestingly, the odds ratio for cardiovascular
disease in GI patients approaches that estimated for type
2 diabetes patients (3). Characteristically, dyslipidemia
associated with insulin resistance consists of hypertriglycer-
idemia and decreased HDL cholesterol levels. LDL choles-
terol levels are not usually elevated, and LDL plasma kinetics
may be normal in type 2 diabetes. Kinetic studies have been
performed by radioactive or stable isotope labeling of apo
B100, which is the only LDL protein (4-8). However,
alterations in LDL metabolism may occur in the lipid part
of the lipoprotein because insulin resistance causes changes
in the LDL subfraction profile, with an increase in the more
atherogenic small-dense LDL subfraction (9).
LDL contains both unesterified and esterified cholesterol.
Each of these forms of cholesterol has distinct physical
chemical and metabolic properties, and their status in the
plasma has not been explored in metabolic diseases affecting
plasma lipids. Esterified cholesterol is located in the
lipoprotein core, wherefrom it can be dislocated only by the
action of transfer proteins. Unesterified cholesterol located in
the lipoprotein surface is a more unstable form of cholesterol.
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Cholesteryl ester transfer protein (CETP) and phospholi-
pid transfer protein (PLTP) promote lipid transfer among
lipoprotein classes, including cholesterol, phospholipids
and triglycerides. These lipid transfers are crucial for the
formation and metabolism of HDL in the plasma and are
part of the reverse cholesterol transport. Free cholesterol
transferred to HDL undergoes esterification by lecithin-
cholesterol acyltransferase (LCAT) using apo A1, which is
the main HDL apolipoprotein, as a co-factor (10,11).
This study aimed to investigate whether insulin resistance
affects the plasma kinetics of lipoprotein free and esterified
cholesterol and the transfer of both cholesterol forms,
phospholipids and triglycerides to HDL, even in the
absence of altered plasma lipids. GI patients with normal
lipid plasma levels were studied to determine whether these
parameters could indicate the existence of metabolic
alterations. An artificial nanoemulsion that mimicked the
LDL structure was used to probe the intravascular
metabolism of LDL cholesterol (12) and also as a lipid
donor to HDL (13) for the in vitro evaluation of the lipid
transfer.
MATERIALS AND METHODS
Subjects
In total, 14 GI individuals and 15 healthy controls, all
without clinical manifestations of cardiovascular disease,
were recruited at the Medical School Hospital of the
University of Sa˜o Paulo and from the an outpatient clinic of
the Heart Institute, and they were paired for age, sex, race
and co-morbidities. All of the patients were submitted to an
electrocardiogram exercise stress test to evaluate the presence
of cardiovascular disease. A negative result indicated an
absence of cardiovascular disease. The electrocardiogram
exercise stress test adopted was the Bruce protocol with a
MAT 2100 treadmill coupled with an ML 800 Stress Test
System (Fukuda Denshi Co., Ltd). The electrocardiographic
recordings of 15 simultaneous leads, with 12 classic deriva-
tions of the Mason - Likar system and 3 leads of the Frank
orthogonal system (X,Y,Z), were obtained.
All patients were submitted to an oral glucose tolerance test
(OGTT) that was performed at 120 min after the patients drank
the glucose solution. According to the American Diabetes
Association criteria (14), GI patients exhibited normal 2 h
plasma glucose levels (7.8-11.1 mmol/L; n = 4) or impaired
fasting glucose levels ($5.5 mmol/L; n = 10). The control group
had 2 h plasma glucose ,7.8 mmol/L and fasting blood
glucose ,5.5 mmol/L.
None of the participants had liver or renal dysfunction as
evaluated by clinical and laboratory criteria. None had
inflammatory, neoplastic or pulmonary disease, chronic
renal disease (creatinine .1.5 mg/dL), asthma, cardiovas-
cular disease, peripheral arterial disease or a previous
stroke. The patients were evaluated by cardiologists to
detect issues related to coronary heart disease (e.g., angina,
dyspnea, palpitations). No patient was taking metformin,
glucocorticoids or any medication known to affect lipid
metabolism.
The inclusion criteria were as follows: age between 40 and
70 years; total cholesterol ,6 mmol/L; LDL-C ,4 mmol/L;
triglycerides ,2.2 mmol/L; normal blood pressure or
treated hypertension up to 130/85 mmHg; and thyroid
function within the normal range or compensated with
thyroid replacement therapy.
Cases and controls did not differ regarding the frequency
of arterial hypertension (8 in GI vs. 5 in controls, p = 0.27);
family history of cardiovascular disease (7 vs. 5, p = 0.46);
family history of type 2 diabetes (8 vs. 4, p = 0.13); current
smoking (1 vs. 1, p= 1.00); hypothyroidism (2 vs. 4, p= 0.65);
and current medications such as angiotensin-converting
enzyme inhibitors (5 vs. 3, p = 0.42), angiotensin II receptor
blockers (1 vs. 2, p= 1.00), calcium channel blockers (1 vs. 3,
p = 0.59), thiazides (6 vs. 3, p = 0.24) and levothyroxine (3 vs.
4, p= 1.00). The characteristics of the study patients are
described in Table 1.
Ethics
The human experimental protocol was approved by the
institutional review boards of the Medical School Hospital
of the University of Sa˜o Paulo and was in accordance with
the Helsinki Declaration of 1975, as revised in 1983. All
participants provided written informed consent.
Laboratory assays
Blood samples for the determination of laboratory para-
meters were collected after fasting for 12 h and on the same
day the kinetic study was performed. Commercial enzymatic
colorimetric methods were used for the determination of total
cholesterol, triglycerides and HDL-C. LDL cholesterol was
calculated using a direct method (kinetic automatized).
Plasma apo A1 and apo B were assayed by turbidimetry
(Roche/Hitachi, Roche Diagnostics, Mannheim, Germany),
Table 1 - Physical characteristics and current medications
of the glucose-intolerant (GI) group and the control
group.
GI
n=14
Control
n = 15 p-value
Age (years) 56¡6 53¡6 0.13
Sex (F/M) 9/5 8/7 0.71
Weight (kg) 78.5¡12 76.5¡8.7 0.63
BMI (kg/m2) 29.8¡4.4 27.6¡2.6 0.13
Waist circumference (cm) 99.7¡10.8 94.7¡12.7 0.26
HOMA2%b 111.9¡27.9 102.9¡34.1 0.44
HOMA2%S 80¡43.1 139.7¡74.7 0.01
HOMA2-IR 1.5¡0.6 0.9¡0.4 ,0.01
Total fat area (cm2) 475.2¡143.9 396.3¡97.7 0.10
Visceral fat area 171.5¡81.9 144.4¡48.1 0.29
Subcutaneous fat area 303.6¡101.7 251.8¡83.1 0.15
Visceral/subcutaneous ratio 0.61¡0.34 0.63¡0.30 0.86
Arterial hypertension 8 5 0.27
Familial history of CVD 7 5 0.46
Family history of type 2
diabetes
8 4 0.13
Current smoking 1 1 1.00
Hypothyroidism 2 4 0.65
Current medications
ACEi 5 3 0.42
ARB 1 2 1.00
Ca2+ channel blockers 1 3 0.59
Thiazides 6 3 0.24
Levothyroxine 3 4 1.00
Data are the means ¡ SD. Differences were assessed using Fisher’s exact
test, Student’s t-test and chi-squared test. HOMA2%b: insulin secretion by
pancreatic b cells; HOMA2%S: insulin sensitivity; HOMA2-IR: index of
insulin resistance (1/HOMAS); CVD: cardiovascular disease; ACEi:
angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor
blocker; SD: standard deviation. Analyses of abdominal fat area by CT
were performed with n=14 for the GI group and n=14 for the control
group.
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and apo E was measured by nephelometry. HbA1C was
measured by HPLC (National Glycohemoglobin Standar-
dization Program (NGSP), USA; normal range 4.1 to 6%).
Plasma insulin was measured by an enzyme-linked immuno-
sorbent assay (AutoDELFIA, Perkin-Elmer Life Science,
Wallac, Oy, Finland) with an intra-assay coefficient of
variation of ,1.5%. The plasma glucose concentration was
measured using a hexokinase method.
Insulin resistance
The fasting plasma glucose (mmol/L) and insulin (rmol/
L) values were used to evaluate insulin resistance via the
Homeostasis Model Assessment (HOMA), which is a
mathematical model for defining insulin secretion by
pancreatic b cells (HOMA2-%b) and insulin sensitivity
(HOMA2-%S) as percentages of normal values and the
index of insulin resistance (HOMA2-IR). This model was
implemented using the HOMA Calculator Version 2.2.2
software, which was developed by The Oxford Center for
Diabetes, Endocrinology & Metabolism (Diabetes Trial Unit,
HOMA Calculator; available at http://www.dtu.ox.ac.uk)
(15).
Computerized tomography of the abdomen
The abdominal fat distribution was evaluated by compu-
terized tomography (CT) of the abdomen without oral or
intravenous contrast or any previous preparation of the
patients. The examination was performed at the Institute of
Radiology of the Medical School Hospital using a high-
speed CT (GE). The initial image acquisition was used as the
‘‘scout’’ (digital radiology) for the patient profile. A single
CT image with a thickness of 10 mm was obtained in the
median of the disc space of L4-L5, guided by the previously
obtained ‘‘scout’’. The visceral and subcutaneous fat areas
were calculated in the CT image. The limits of the fat
component were calculated using the upper limit of -50
Hounsfield units and the lower limit of -250 Hounsfield
units as the attenuation values to determine the presence of
fat in the bound area. The ratio of the visceral and
subcutaneous fat areas was also calculated (16).
LDE preparation
The LDE was prepared from a lipid mixture composed of
40 mg cholesteryl oleate, 20 mg egg phosphatidylcholine,
1 mg triolein and 0.5 mg cholesterol purchased from Sigma
Chemical, USA. 14C-cholesteryl oleate and 3H-cholesterol
were purchased from Perkin-Elmer, USA, and added to the
mixture. The emulsification of the lipids by prolonged
ultrasonic irradiation in aqueous media and the two-step
ultracentrifugation of the crude emulsion with density
adjustment by the addition of KBr to obtain the LDE were
performed as described by Maranha˜o et al. (17). The final
lipid composition of the LDL-like LDE was 64% phospho-
lipids, 33% cholesteryl oleate, 2% triacylglycerols and 1%
cholesterol. The LDL-like LDE was dialyzed against a saline
solution and sterilized by passage through a 0.22-mm filter
before injection into the patients. The entire LDE prepara-
tion procedure was performed under laminar flow. All
glassware used in this study was made pyrogen-free by
exposure to dried steam at 180 C˚ for 2 h and sterilized by
wet steam at 120 C˚ for 30 min. All plastic materials were
sterilized by ultraviolet light exposure.
Plasma kinetics study protocol
As previously indicated, the study patients were asked to
arrive at the laboratory at 7 a.m., after a 12-h fasting period.
Blood samples were collected as described previously for
the determination of basal blood parameter levels. The LDE
labeled with 14C-cholesteryl oleate (37kBq) and 3H-free
cholesterol (74 kBq) was injected intravenously in a bolus of
5-6 mg of total lipids in a 500-mL volume. Blood samples
were obtained over 24 h (5 min, 1 h, 2 h, 4 h, 6 h, 8 h and
24 h). The subjects were allowed to eat low-fat meals on the
evening before the test day, after the first blood collection
and at about 1500 p.m. because low-fat meals do not
interfere with the plasma removal of LDE (17). The plasma
samples were separated by centrifugation, and 1 mL of each
sample was transferred to a counting vial containing 5 mL
of scintillation solution. The samples were then counted in a
scintillation counter (1600 TR model, Hewlett-Packard, Palo
Alto, CA).
Estimation of the fractional clearance rate of the
radioisotopes
The fractional clearance rates (FCRs) of 14C-cholesteryl
ester and 3H-free cholesterol from the LDE were calculated
according to the method described by Couto et al. (18).
FCR = (a1/b1+a2/b2)21, where a1, a2, b1 and b2 were
estimated from biexponential curves obtained from the
remaining radioactivity found in the plasma after injection
and fitted by least squares procedure as y = a1e-b1t+a2e-b2t,
where y is the curve of the radioactivity plasma decay as a
function of time (t); a indicates the linear coefficient and b is
the angular coefficient, which represents the FCR (h-1).
Calculations were performed using ANACOMP computer
software (19). The compartmental model is illustrated in
Figure 1.
In vitro lipid transfer from LDE to HDL
The assay to estimate the lipid transfer of 3H-cholesteryl
oleate, 14C-phosphatidylcholine, 3H-triolein and 14C-free
cholesterol from the LDE to HDL was performed as
described by Lo Prete et al. (13). The assay is based on a
1-h incubation of the LDE with whole plasma, followed by
the measurement of the radioactivity in the supernatant
after the chemical precipitation of the non-HDL lipoprotein
fractions and of the LDE. The safety of the radioactive dose
intravenously injected into the patients was assured
according to the regulations of the International Comm-
ission on Radiological Protection (20). The injected dose in
each experiment was 0.03 mSV.
Statistical analysis
The results are expressed as means¡ standard deviations
(mean ¡ SD). Student’s t-test was used to compare the
means of the two groups. When the assumption of normal-
ity was rejected, the non-parametric Mann-Whitney test was
used. To test the homogeneity between the proportions, the
chi-squared or Fisher’s exact test was used. To study the
influence of two factors on abdominal adiposity, a two-way
analysis of variance was used. The coefficient of correlation
was determined to study the correlation between two
variables. Statistical analyses were performed using SPSS
15.0 for Windows. Differences with p,0.05 were considered
to be significant.
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RESULTS
GI patients and controls did not differ regarding the area
of total abdominal fat (p= 0.10) or visceral (p = 0.29) and
subcutaneous fat (p= 0.15) as evaluated by abdominal CT
(Table 1).
There was no difference between GI patients and controls
with respect to b cell insulin secretion as indicated by
HOMA2%b (p = 0.44) (Table 1). The fasting insulin concen-
tration (p,0.01) and the insulin resistance index (p,0.01)
were higher in the GI patients than in controls (Table 1 and
Table 2). As expected, compared with controls, the GI
subjects had lower insulin sensitivity as expressed by
HOMA2%S (p = 0.01).
The plasma biochemical parameters of the study groups
are shown in Table 2. The concentrations of total, LDL, non-
HDL and HDL cholesterol and triglycerides were similar in
GI patients and controls. Similarly, apo A1 and apo B did
not differ between the two groups. Apo E tended to be
lower in GI patients than in controls, but this difference did
not attain statistical significance (p= 0.06).
The plasma decay curves of both LDE labels are shown in
Figure 2. The cholesteryl ester curves of GI patients and
control subjects were equal (Figure 2A), as confirmed by the
cholesteryl ester FCR shown in Table 3. However, the free
cholesterol curve (Figure 2B) was faster in GI patients than
in controls, as confirmed by a greater free cholesterol FCR
(p = 0.04) (Table 3).
Table 4 shows the results of the in vitro transfer of the four
radioactive lipids from the donor LDE to the HDL fraction
after incubation of the LDE with whole plasma. GI patients
did not show differences in the transfer of lipids compared
with the control group.
Correlations were found between free cholesterol FCR
and LDL cholesterol (r = -0.53, p= 0.04) and apo E (r = -0.55,
p = 0.03); between phospholipid transfer to HDL and LDL
cholesterol (r = 0.57, p= 0.03) and apo B (r = 0.64, p = 0.01);
between triglyceride transfer to HDL and fasting insulin
(r = -0.55, p= 0.03), insulin sensitivity (r = 0.53, p= 0.04) and
insulin resistance (r = -0.53, p= 0.04); and between free
cholesterol transfer to HDL and LDL cholesterol (r = -0.55,
p = 0.04), HDL cholesterol (r = 0.54, p = 0.04), plasma trigly-
cerides (r = -0.76, p,0.01), apo B (r = -0.70, p,0.01) and apo E
(r = -0.58, p = 0.02).
DISCUSSION
The stable isotope method traces the kinetics of the
protein component of lipoproteins. Alternatively, the radio-
active nanoemulsion method used here traces the kinetics of
the lipid components. When the LDE is injected into the
bloodstream, it acquires apo E from the native lipoproteins
and binds to LDL receptors that recognize both apo B and
apo E (17,21). Because apo E has greater affinity for the LDL
receptor than apo B, the LDE is removed more quickly from
the plasma compartment than native LDL. This effect is
advantageous because it shortens the observation time
required (17,21,22). This method was validated in several
experimental (17,23) and clinical studies (12,18,24-26), in
which the kinetic behavior of the nanoemulsion was similar
to that expected from native LDL.
The interpretation of plasma removal data after a bolus
injection is straightforward. In addition, a single preparation
can be used in several subjects, and the radioactive dose is
very low, in accordance with the radiological protection
international standards.
Using the LDE approach, we showed that the cholesteryl
ester moiety is cleared equally in GI and control patients.
Because the cholesteryl ester is less prone to dissociate from
LDE particles (i.e., it can only be dissociated through CETP
activity), it may be used an approximate marker of the
plasma removal of the nanoemulsion particles. This
Figure 1 - Compartmental model used to analyze the LDE 14C-
cholesteryl ester (CE) and 3H-free cholesterol (FC). The model
consists of four discrete compartments: two for 14C-CE and two
for 3H-FC. All compartments are in the intravascular space (1CE,
2CE, 1FC and 2 FC). LDE
14C-CE and 3H-FC are injected intravenously
in a bolus (arrow with asterisk) into compartments 1CE and 1FC,
respectively. Fractions k1,0 CE and k1,0 FC of the labeled lipids are
removed to the extravascular space. Fractions k1,2 CE and k1,2 FC
of the injected lipids are converted into compartments 2CE and
2FC because of the incorporation of apolipoproteins available in
the plasma. Subsequently, the materials of those compartments
are transferred to the extravascular space following the k2,0 CE
and k2,0 FC routes. The samplings, represented by triangles,
correspond to the indiscriminate combination of compartments
1 and 2.
Table 2 - Serum biochemical parameters of the glucose-
intolerant (GI) group and the control group.
GI
N=14
Control
N=15 p-value
Fasting glucose (mmol/
L)
5.61¡0.4 4.78¡0.2 ,0.01
2-h postload glucose
OGTT (mmol/L)
8.91¡0.7 5.83¡1.1 ,0.01
Fasting insulin (mU/mL) 11.9¡5.1 7.1¡3.7 ,0.01
HbA1C (%) 6.1¡0.5 5.6¡0.3 0.02
Cholesterol (mmol/L) 5.07¡0.6 4.82¡0.67 0.35
Non-HDL 3.67¡0.7 3.42¡0.5 0.34
LDL-C 3.02¡0.6 2.85¡0.5 0.47
HDL-C 1.37¡0.4 1.37¡0.5 0.99
Triglycerides (mmol/L) 1.44¡0.4 1.26¡0.4 0.27
Apolipoproteins (g/L)
A1 1.53¡0.29 1.5¡0.35 0.86
B 0.99¡0.24 0.91¡0.18 0.33
E 0.05¡0.01 0.04¡0.01 0.06
Data are the means¡SD. Student’s t-test. OGTT: oral glucose tolerance
test; SD: standard deviation.
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assumption is corroborated by the transfer assay (Table 4),
which showed that the shift of cholesteryl esters from the
nanoemulsion to HDL is small: 3.6%, compared with
roughly 10% for free cholesterol and 22% for phospholipids.
LDL removal with radiolabeled apo B from the plasma of
subjects with GI has not been described in the literature. In
subjects with metabolic syndrome (4,27,28) or obesity (5),
which are conditions in which insulin resistance is
presumptively involved, LDL apo B plasma removal was
found to be slower than in control subjects. However, the
participants of those studies had elevated LDL cholesterol
and triglyceride levels (4,27,28) whereas our GI patients did
not.
An important finding of this study was the fact that the
free cholesterol component of the LDE was removed more
quickly in GI patients than in controls. This finding suggests
that in GI patients, the unesterified cholesterol may
dissociate from the surface of the lipoprotein particles and
was independently and more rapidly cleared from the
Figure 2 - Decay curves of the LDE 14C-cholesteryl ester (a) and 3H-free cholesterol (b) obtained from the glucose-intolerant (GI) and the
control group. Double-labeled LDE was intravenously injected in a bolus, and blood samples were drawn in pre-established intervals
over 24 h for measurement of the radioactivity in the scintillation solution. Data are presented as the % of the radioactivity counting
considering the first point as 100% and are expressed as the means¡SD. Black squares: GI group; white squares: control group.
Table 3 - Fractional clearance rate (FCR) and kinetic
parameters of LDE 14C-cholesteryl ester and 3H-free
cholesterol in the glucose-intolerant group (GI) and in
the control group.
GI
n=14
Control
n = 15 p-value
FCR 14C-CE 0.05¡0.01 0.05¡0.01 0.40
k 1.0
14C-CE 0.26¡0.18 0.24¡0.23 0.48
k 1.2
14C-CE 0.33¡0.17 0.59¡0.61 0.19
k 2.0
14C-CE 0.04¡0.01 0.06¡0.07 0.96
FCR 3H-FC 0.06¡0.02 0.04¡0.02 0.04
k 1.0
3H-FC 0.54¡0.35 0.66¡0.24 0.34
k 1.2
3H-FC 0.48¡0.19 0.44¡0.21 0.62
k 2.0
3H-FC 0.05¡0.10 0.02¡0.01 0.01
Data are expressed as the means¡SD. Student’s t-test and unpaired
Mann-Whitney test. FCR: fractional clearance rate; CE: cholesteryl ester;
FC: free cholesterol; k1,0: kinetic parameters for the removal of lipids from
the intravascular compartment; k1,2: kinetic parameters that receive
apolipoproteins from the intravascular compartment; k2,0: kinetic
parameters for the removal of the LDL-like nanoemulsion attached to the
apolipoproteins from the intravascular compartment; SD: standard
deviation.
Table 4 - In vitro lipid transfers from the LDE to the HDL
fraction in the glucose-intolerant group (GI) and in the
control group (measured as the % of the total
radioactivity of each LDE lipid incubated with whole
plasma and recovered after 1 h in the HDL fraction).
LDE lipid transfer to
HDL
Gl
n=14
Control
n = 15 p-value
Cholesteryl esters 3.5¡0.4 3.6¡0.6 0.63
Phospholipids 21.6¡1.1 22.2¡1.2 0.19
Triglycerides 7.0¡2.1 6.1¡1.3 0.15
Free cholesterol 9.2¡1.1 9.9¡2.0 0.29
Data are expressed as the means¡SD. Student’s t-test and unpaired
Mann-Whitney test.
SD: standard deviation.
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circulation. However, the cholesteryl esters persisted in the
core of the LDE particles.
In a previous study (29), we identified a similar kinetic
behavior for LDE unesterified and esterified cholesterol in
normocholesterolemic patients with coronary heart disease.
Upon injection of the LDE, free cholesterol was removed
faster in diseased patients than in controls (29). The
association of this behavior with coronary heart disease
suggests that free cholesterol may desorb from LDE
particles and deposit in the arteries (12). In this respect,
after the injection of the LDE into patients with coronary
heart disease that were scheduled for revascularization
surgery, there was proportionally more free than esterified
cholesterol in the fragments of the vessels discarded during
the surgery (18). This result supports the hypothesis that
after shifting from LDE particles, free cholesterol precipi-
tates in the vessels and will eventually disturb endothelial
homeostasis, which is a primordial triggering mechanism in
atherogenesis.
The lipid transfer process is dependent upon the HDL
composition and therefore may affect the adhesion of
proteins to the lipoprotein surface. Thus, the function of
HDL in not only reverse cholesterol transport but also other
atheroprotective functions, such as the antioxidant, anti-
inflammatory, anti-apoptotic, vasodilatory, antithrombotic
and anti-infectious activity, may be affected by this process
(30).
Low HDL cholesterol is a marker of metabolic syndrome
and may also be diminished in GI patients (31), although
normal levels have also been described (32-35). In our GI
patients, HDL was within the normal range and did not
differ from the levels in the control subjects. Furthermore,
we found no difference between GI patients and the controls
with respect to the in vitro transfer of the four LDE labeled
lipids to HDL. In GI, as in type 2 diabetes, the action of
CETP was found to be enhanced (31,33,37). However, other
factors such as the normal HDL cholesterol concentration
may have counteracted the eventual increase in the transfer
of cholesteryl esters and triglycerides that would be
facilitated by CETP (10,30).
Note that in the abovementioned studies, the levels of
HDL cholesterol were lower in the experimental groups
than in the controls whereas, in the present study, this
parameter did not differ between groups. However, PLTP,
which transfers phospholipids and also facilitates the
transfer of free cholesterol, was described as normal in GI
patients (36).
An interesting finding of our study was the positive
correlation between the transfer of free cholesterol and the
HDL levels. In contrast, the three other lipids that are more
dependent on transfer proteins for transport did not
correlate with the HDL levels. This finding highlights the
importance of HDL for the reception of free cholesterol for
subsequent esterification. Because of the importance of this
lipoprotein as the main esterification site, a deficiency in
free cholesterol reception when HDL levels are low may be
a major mechanism that links HDL cholesterol levels and
atherosclerosis (13,37,38).
In conclusion, GI subjects without dyslipidemia or clinical
manifestations of cardiovascular disease had normal in vitro
transfer of lipids to HDL and removal of the LDL
nanoemulsion probe from the plasma. The latter finding
may account for their normal LDL cholesterol levels.
Nonetheless, the GI patients exhibited an abnormal kinetic
behavior of free cholesterol that may be associated with
atherogenesis. This finding is important for the under-
standing of the overall role of insulin resistance in the
pathophysiology of cardiovascular disease.
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